RecruitingNot ApplicableNCT06078436

Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF

Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Caused by Heart Failure With Reduced Ejection Fraction

Sponsor

Min-Seok Kim

Enrollment

160 participants

Start Date

Jan 1, 2024

Study Type

INTERVENTIONAL

Conditions

Cardiogenic Shock Heart Failure With Reduced Ejection Fraction

Summary

This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether starting carvedilol (a heart medication) early, guided by a pulmonary artery catheter (a device that measures pressures inside the heart and lungs), improves outcomes in patients experiencing cardiogenic shock — a dangerous condition where the heart suddenly can't pump enough blood. **You may be eligible if...** - You are 19 years old or older - You are in cardiogenic shock related to heart failure with reduced ejection fraction (HFrEF) and being monitored in an ICU - You are able to take oral medications - You have provided written consent to participate **You may NOT be eligible if...** - You cannot take oral medications - You are in shock for reasons other than HFrEF - You are unable to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.